Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-01-25
2005-01-25
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S557000
Reexamination Certificate
active
06846842
ABSTRACT:
A therapeutic composition comprising an alkyl, aralkyl, alkoxyalkyl or carboxyalkyl ester of 2-ketoalkanoic acid and a component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is disclosed. The composition of the invention further comprises a pharmceutically acceptable carier vehicle in which the enol resonance form of the ester is stabilized at physiological pH values. Formulations containing the compositions of the invention permit the successful use of 2-ketoalkanoic acid esters, e.g., pyruvic acid esters, to treat, e.g., ischemic events, shock, organ reanimation, resuscitation and other recognized pyruvate-effective treatments. The compositions of the inventions are also useful in a process for preserving organ parts, organs or limbs removed from a living mammal and in need of preservation, e.g., for later transplantation to an organ recipient.
REFERENCES:
patent: 3920835 (1975-11-01), Van Scott et al.
patent: 3984556 (1976-10-01), Hardtmann
patent: 3988470 (1976-10-01), Van Scott et al.
patent: 4351835 (1982-09-01), Stanko
patent: 4415576 (1983-11-01), Stanko
patent: 4548937 (1985-10-01), Stanko
patent: 4645764 (1987-02-01), Stanko
patent: 4812479 (1989-03-01), Stanko
patent: 4874790 (1989-10-01), Stanko
patent: 4970143 (1990-11-01), Guidoux et al.
patent: 4981687 (1991-01-01), Fregly et al.
patent: 4988515 (1991-01-01), Buckberg
patent: 5066578 (1991-11-01), Wikman-Coffelt
patent: 5075210 (1991-12-01), Wikman-Coffelt
patent: 5100677 (1992-03-01), Veech
patent: 5134162 (1992-07-01), Stanko
patent: 5147650 (1992-09-01), Fregly et al.
patent: 5210098 (1993-05-01), Nath
patent: 5256697 (1993-10-01), Miller et al.
patent: 5294641 (1994-03-01), Stanko
patent: 5312985 (1994-05-01), Dhaon et al.
patent: 5395822 (1995-03-01), Izumi et al.
patent: 5472980 (1995-12-01), Miller
patent: 5480909 (1996-01-01), Stanko
patent: 5508308 (1996-04-01), Miller et al.
patent: 5536751 (1996-07-01), Bunger
patent: 5580902 (1996-12-01), Yu et al.
patent: 5612374 (1997-03-01), Stanko
patent: 5633285 (1997-05-01), Martin
patent: 5648380 (1997-07-01), Martin
patent: 5652274 (1997-07-01), Martin
patent: 5658957 (1997-08-01), Martin
patent: 5667962 (1997-09-01), Brunengraber et al.
patent: 5702880 (1997-12-01), Segall et al.
patent: 5714515 (1998-02-01), Bunger
patent: 5744498 (1998-04-01), Stanko
patent: 5756469 (1998-05-01), Beale
patent: 5798388 (1998-08-01), Katz
patent: 5801198 (1998-09-01), Stanko et al.
patent: 5843024 (1998-12-01), Brasile
patent: 5863938 (1999-01-01), Martin
patent: 5874479 (1999-02-01), Martin
patent: 5876916 (1999-03-01), Brunengraber et al.
patent: 5952384 (1999-09-01), Katz
patent: 5968727 (1999-10-01), Brunengraber et al.
patent: 6086789 (2000-07-01), Brunengraber et al.
patent: 6143784 (2000-11-01), Greenhaff et al.
patent: 0 108 820 (1986-10-01), None
patent: WO 9741848 (1997-11-01), None
patent: WO 9804127 (1998-02-01), None
patent: WO 9851277 (1998-11-01), None
patent: WO 9921544 (1999-05-01), None
Banda, M.A. and Granger, D.N., “Mechanism and Protection from Ischemic Intestinal Injury,”Transplantation Proceedings,28:2595-2597 (1996).
Cicalese, L., et al., “Pyruvate Prevents Ischemia-Reperfusion Mucosal Injury of Rat Small Intestine,”Amer. J. of Surg.,171:97-100; discussion 100-101 (1996).
Crestanello, J.A., et al., “Pyruvate Improves Myocardial Tolerance to Reperfusion Injury by Acting as an Antioxidant: A Chemiluminescence Study,”Surgery,124:92-99 (1998).
DeBoer, L.W., et al., “Pyruvate Enhances Recovery of Rat Hearts After Ischemia and Reperfusion by Preventing Free Radical Generation,”American Journal of Physiology,265:H1571-H1576 (1993).
Kurose, I., et al., “Ischemia/Reperfusion-Induced Microvascular Dysfunction: Role of Oxidants and Lipid Mediators,”Amer. J. Physiol.,272:H2976-H2982 (1997).
Margolis, S.A. and Coxon, B., “Identification and Quantitation of the Impurities in Sodium Pyruvate,”Analytical Chemistry,58:2504-2510 (1986).
O'Donnell-Tormey, J., et al., “Secretion of Pyruvate. An Antioxidant Defense of Mammalian Cells,”J. of Experimental Medicine,165:500-514 (1987).
Perera, A., et al., “High Resolution1H NMR Investigations of the Reactivities of Alpha-Keto Acid Anions with Hydrogen Peroxide,”Free Radical Research,26:145-157 (1997).
Salahudeen, A.K., et al., “Hydrogen Peroxide-induced Renal Injury: A Protective Role for Pyruvate In Vitro and In Vivo,”Journal of Clinical Investigation,88:1886-1893 (1991).
Sawyer, D.T., et al., “Reactivity of Superoxide Ion with Ethyl Pyruvate, α-Diketones, and Benzil in Dimethylformamide,”Journal of Organic Chemistry,48:3733-3736 (1983).
Starostin, E.K., et al., “Decomposition of the Peroxides of the Esters of Keto Acids by Fe(II) Salts,”Bulletin of the Academy of Sciences of the USSR Division of Chemical Science,29:109-112 (1980).
Varma, S.D., et al., “Prevention of Intracellular Oxidative Stress to Lens by Pyruvate and Its Ester,”Free Radical Research,28:131-135 (1998).
Sims, C.A., et al., “Intravenous Pyruvate and Pyruvate Ethyl Ester Ameliorate Intestinal Mucosal Injury Following Ischemia/Reperfusion,”Surgical Forum,vol. L: 246-248 (1999).
Bünger, R., et al., “Pyruvate-enhanced Phosphorylation Potential and Inotropism in Normoxic and Postischemic Isolated Working Heart,”European Journal of Biochemistry,180(1):221-223 (1989).
Borle, A.B. and Stanko, R.T., “Pyruvate Reduces Anoxic Injury and Free Radical Formation in Perfused Rat Hepatocytes,” The American Physiological Society, G535-G540 (1996).
Ajami Alfred M.
Fink Mitchell P.
Sims Carrie A.
Beth Israel Deconess Medical Center, Inc.
Hamilton Brook Smith & Reynolds P.C.
Jagoe Donna
Low Christopher S. F.
Xanthus Life Sciences, Inc.
LandOfFree
Pyruvate ester composition and method of use for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyruvate ester composition and method of use for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyruvate ester composition and method of use for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3378250